7 Multibagger Ideas: Quality Small-Cap Stocks (2026)
These stocks have it in their DNA to become multibaggers.
New to The Atomic Moat? If you want more multibagger lists such as this sent to your inbox, join 1,500+ other investors below.
First, let’s kill the word
“Multibagger” is a clickbait word. I know it, you know it, and the algorithm knows it. So let me defuse it before we go any further.
A multibagger is a business that compounds its value at a high rate, held for a long time. That’s it. The multiple is arithmetic, not magic.
Watch how fast the arithmetic runs. A business that compounds intrinsic value at 20% a year turns into roughly a 6-bagger in ten years, a 15-bagger in fifteen, and a 95-bagger in twenty-five.
Berkshire became one of the great 100-baggers of all time the boring way: it compounded at around 20% for sixty years. Buffett bought predictable, wonderful businesses at fair prices and then did the hardest thing in investing, which is nothing.
“The big money is not in the buying and the selling, but in the waiting.” — Charlie Munger
So when I screen for “multibaggers,” I am really screening for three ingredients, and I want you to use the same three on every name below:
A durable compounding engine. A high return on capital that the business can actually reinvest, not just earn once. The return on the next dollar is what matters, not the average return on the dollars already spent.
A long runway. Room to keep redeploying cash at that high rate for a decade or two. A brilliant business with no room to grow is a lovely dividend stock and a poor wealth-builder.
Hold-ability. Enough predictability that you can sit through the three 50% drawdowns every one of these will hand you without selling at the bottom. This is the ingredient everyone ignores, and it is the one that actually decides whether you collect the multiple or just admire it from the exit.
There is a fourth thing that turns a good return into a spectacular one, and it is not what most people think.
Total return comes from two engines: growth in the business, and a change in the valuation multiple.
For a real long-run winner the growth does the heavy lifting, tens of times over. The multiple re-rating is a 2x to 3x kicker on top. That kicker is not bargain-hunting. It is the market slowly admitting it had the wrong label on a business, and the day it admits that is the day your thesis pays you twice.
One last thing about where these live. A famous study of 104 stocks that returned more than 350% over five years found the winners clustered in Sweden, the UK, Germany, Norway, and Australia, with thin analyst coverage, and 84% of them started under $2 billion in market cap. Small, neglected, developed-market businesses are the pond.
Five of the seven names below are fishing in exactly that water. Two are not, and I will tell you which.
Disclaimer: All content is for informational and entertainment purposes only and does not constitute financial advice.
The seven
These come in three flavours.
The compounding machines own the process of getting bigger. The fallen quality names are good businesses the market has thrown out with the bathwater. The asymmetric bets are smaller, spicier, and more binary, where the upside is large and so is the way you can be wrong.
Let’s get to it.
1. Teqnion (TEQ)
Building something for the next 100 years
What it is
Teqnion is a Swedish serial acquirer. It buys small, profitable, gloriously dull industrial companies, the kind that make connectors, transformers, lab equipment, and indication systems for military practice shooting, and then it leaves them alone to keep doing what they were already good at. Founder and CEO Johan Steene talks openly about building a company that lasts a hundred years, and he runs it like someone who means it: decentralised, cash-focused, allergic to head-office empire-building.
The numbers today
The stock trades around SEK 158, for a market cap near SEK 2.5 billion, which is about $255 million. Full-year 2025 revenue was roughly SEK 1.8 billion with net income near SEK 98 million, putting the shares around 28 times earnings. There is no dividend, by design. Every krona that comes in goes back out to buy the next business. The stock is up modestly over the past year and has spent twelve months bouncing between SEK 136 and SEK 189.
The runway
This is the part that matters. There are tens of thousands of small, owner-run industrial niche businesses across the Nordics and Europe whose founders will eventually want to retire and sell to a good home. Teqnion is a rounding error against that universe. A serial acquirer this size does not have a TAM problem; it has a “can we keep finding good deals and not overpay” problem. The engine is the acquisition process itself: the culture, the discipline, the decentralisation. The product could change entirely and the moat would still be there.
Why it could be a multibagger
The model is proven. Constellation Software, Lifco, Lagercrantz, and Indutrade all turned the same playbook into double-digit-to-twenty-percent per-share compounding for decades. Teqnion is early on that curve and small enough that its size edge is real, which is exactly the combination the data says you want. If Steene keeps buying well, a small base compounding in the high teens for twenty years is the whole multibagger story, and it requires no heroics.
What has to go right, and what could break it
A serial acquirer is only as good as its discipline. The headline P/E looks pricey because acquisition goodwill sits on the balance sheet and drags reported returns down; the honest way to judge Teqnion is the return on tangible capital and the return on each new acquisition, and that is the thing to watch every year. The risks are the obvious ones for the model: overpaying as it scales, diluting shareholders if it issues too many shares to fund deals, and the simple fact that the businesses underneath are lower-margin industrials, not asset-light software. None of that is fatal. All of it is worth watching.
2. Röko (ROKO B)
Lifco 2.0, run by the man who built Lifco
What it is
Röko is the same serial-acquirer idea as Teqnion, scaled up and run by serious pedigree. It was founded in 2019 and chaired by Fredrik Karlsson, the former CEO who compounded Lifco into one of Europe’s great acquisition machines. Röko buys majority stakes in profitable European niche leaders, mostly businesses with EBITA between two and ten million euros, and keeps them forever under a decentralised model that preserves each company’s name and independence. It listed its B shares in Stockholm in March 2025.
The numbers today
The stock trades around SEK 1,900, for a market cap near SEK 28 billion, which is roughly $2.9 billion. That makes Röko comfortably the largest name on this list, and I want to be straight about that: at this size it is not a small cap, and it does not get my pure small-cap edge. It trades around 37 times earnings. Net sales were about SEK 6.2 billion for 2024, with adjusted EBITA margins around 20%, and in the first quarter of 2026 it grew organic sales 6% and total sales 9%, with three more acquisitions closed. It has done over thirty platform deals since inception.
The runway
Same answer as Teqnion, just with deeper pockets and a wider net across the UK, the Nordics, the Netherlands, the US, and beyond. The European long tail of family-owned niche businesses is effectively bottomless relative to even a SEK 28 billion acquirer. The constraint is capital discipline and deal flow, never market size.
Why it could be a multibagger
You are buying a proven operator running a proven playbook with a runway measured in decades. Karlsson has done this before at enormous scale, and the whole point of the perpetual-owner model is that it gets compounding-friendlier as the portfolio diversifies. If Röko sustains high-teens compounding of per-share value over fifteen to twenty years, the math takes care of itself.
What has to go right, and what could break it
The 37x multiple is the honest problem. It already prices in a lot of future success, which means the second engine, the multiple, has less room to help you and more room to hurt you if growth disappoints. The model runs on continuously deploying capital at good returns; the day acquisitions get too expensive or integration slips, the flywheel slows. And it is still young as a public company, so the seasoned track record is shorter than Lifco’s was when it earned its reputation. This is the quality-at-a-full-price name in the group. You are paying up for the pedigree.
3. ChemoMetec (CHEMM)
Selling picks and shovels to the cell-therapy gold rush
What it is
ChemoMetec is a Danish company that makes the NucleoCounter, an instrument that counts cells, and then sells the consumable cassettes and reagents that the instrument eats every time it runs. It is a razor-and-blade business pointed at one of the best end-markets in science: bioprocessing, and the booming world of cell and gene therapy. Crucially, it does not bet on any single drug working. It sells the equipment that every lab in the field needs no matter whose drug wins, which is the cleanest way to own a gold rush.
The numbers today
The stock trades around DKK 315, for a market cap near DKK 5.4 billion, which is about $0.8 billion. It earns roughly DKK 10 per share, so it trades around 31 times earnings. The economics are gorgeous: gross margins around 91%, EBITDA margins around 50%, net cash, and a small dividend. Here is the kicker that makes it interesting right now: the stock is down roughly 72% from its 2021 peak of DKK 1,149, and it has traded between DKK 235 and DKK 804 in the past year alone. Analysts covering it carry an average target up near DKK 640.
The runway
Cell and gene therapy is still early, and every approved therapy and every new manufacturing line needs cell counting as a basic, repeated, non-negotiable step. The recurring consumables grow with the installed base, and the installed base grows with the industry. On top of that, management is now pushing a new “XM” platform and talking about a more software-and-licensing-shaped business over time, which is the kind of pivot that, if it works, re-rates the whole company.
Why it could be a multibagger
Start with a 90%-plus gross margin, net-cash, recurring-consumables compounder. Knock 70% off its price. Add a software transition that could change how the market values it. That is a recipe for both engines firing at once: earnings recovering as the cell-therapy cycle turns, and the multiple expanding as the market re-rates a saturated-looking instrument maker back into a growth compounder.
What has to go right, and what could break it
Even after a brutal de-rating, 31 times earnings is not cheap, so this is not a statistical bargain; it is a quality compounder you are buying at a fair-to-rich price after a fall. The reason it fell is real: the NucleoCounter base started to saturate and growth stalled, which is why the stock got cut in half and then some. The XM platform transition is unproven, and “we are becoming a software company” is a sentence that has humbled many a hardware business. Cell-therapy capital spending is also lumpy. You are betting that the franchise is durable and the next chapter works.
